Trans-arterial embolization for hemoptysis in lung transplant recipients

Respir Med Res. 2022 Nov:82:100941. doi: 10.1016/j.resmer.2022.100941. Epub 2022 Jul 28.

Abstract

Introduction: Hemoptysis isn't rare in lung transplant recipients (LTR). Yet, trans-arterial embolization (TAE) in LTR has been rarely reported in the literature. The aim of the study was to present the feasibility and outcomes of TAE for hemoptysis in LTR.

Materials and methods: Retrospective study of all LTR who underwent TAE for hemoptysis in our single institution between 2005 and 2020.

Results: A total of 787 patients underwent lung transplantation between 2005 and 2020. Fifteen LTR underwent 21 TAE for hemoptysis in a median delay of 42 days after LT. TAE was performed within a year after LT in 13 patients (86.7%) with 12 of those patients having concomitant severe ischemic airway injury with necrosis and anastomotic dehiscence. Bronchoscopy confirmed bronchial anastomoses has being the source of the bleeding in 11 LTR (84.6%). Restoration of bronchial vascularization was highlighted in 13 patients (87%). Despite TAE, bronchial anastomosis healing was observed in all surviving patients with anastomotic dehiscence in a median delay of 43 days.

Conclusion: In our experience, hemoptysis requiring TAE in LTR was rare, frequently occurring in the first weeks after LT, and seemed associated with anastomotic ischemia and dehiscence. Bleeding mainly originated from ischemic bronchial anastomosis through the restoration of the bronchial artery circulation. Our results suggest that bronchial arteriography should be routinely proposed in such patients in the event of hemoptysis.

Keywords: Embolization; Hemoptysis; Lung transplantation.

MeSH terms

  • Hemoptysis* / etiology
  • Hemoptysis* / therapy
  • Humans
  • Lung
  • Retrospective Studies
  • Transplant Recipients*
  • Treatment Outcome